Skip to main
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

United Therapeutics is poised for long-term growth due to its strong focus on the prostacyclin pathway for treating PAH and its market-leading position in this disease space. The company's diverse portfolio of commercialized products and ongoing research in new indications such as IPF and PH-ILD, as well as its plans to launch the treprostinil soft mist inhaler, show potential for continued success. Furthermore, the company's impressive financial results and favorable response from key opinion leaders in the field of PAH bode well for its future growth and positioning as a key player in the PAH market.

Bears say

United Therapeutics is facing potential limitations in its market expansion plans, as discussions around expanding Tyvaso into IPF are influenced by uncertainty around the drug's antifibrotic activity versus its treatment of accompanying pulmonary vascular disease. Additionally, while there is potential for Tyvaso to address a broad IPF treatment role, the company faces significant competition in this market as well as potential regulatory challenges. Given these factors, the company's stock may struggle in the long term.

United Therapeutics (UTHR) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 11 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $640.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $640.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.